Fibrosoft is an Australian company developing a safe, non-surgical injectable therapy for fibrotic conditions (starting with Dupuytren's disease) by repurposing long-approved drugs, targeting a multi-billion dollar market dominated by painful, expensive, or inaccessible options.

The Problem:

• Large Market: Dupuytren's affects ~35% over 65, causing debilitating hand contractures (Global TAM>US$5B)

• Dupytren’s contracture in the hands affects over 75% over 75 years old of European ancestry

• Frozen shoulder (~3-5% of the general population, particularly affects women > 4-5 times than in men and is significantly higher in the elderly).

• Poor Options: Current standards are surgery (15-20% complication risk) or Xiaflex (painful, >$30K, US-only, with safety issues).

• Unmet Need: No safe, effective, affordable, & globally accessible pharmaceutical treatment exists.